drugset
drugset / Trial / NCT04739865

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865 ↗

Phase 2 Completed 19 enrolled COMPASS Pathways
NaSingle-groupOpen-labelTreatment

Summary

The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression

Timeline

Start
2020-08-10
Primary completion
2021-10-14
Completion
2021-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg —

Indications

No indication recorded.